Rational therapy with hematopoietic growth factors G-CSF and GM-CSF;Rationale therapie mit den hämatopoetischen wachstumsfaktore, G-CSF und GM-CSF

Onkologe

Volumn 7, Issue 12, 2001, Pages 1329-1341

  Link, H ^a   Hess, C F ^b   Albers, P ^c   Schmoll, H J ^d   Reimers, H J ^e   Von Minckwitz, G ^f   Nowrousian, M R ^g   Welte, K ^h  

^a Westpfalz Klinikum GmbH   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e Klinik Bad Oexen   (Germany)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; AGRANULOCYTOSIS; APLASTIC ANEMIA; CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; HUMAN; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0035681045     PISSN: 09478965     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007610170009     Document Type: Review

References (100)

1. Rationale Therapie mit G-CSF und GM-CSF
2. Granulocyte colony stimulating factor and granulocytemacrophage colony stimulating factor (2)
3. Granulocyte colony stimulating factor and granulocytemacrophage colony stimulating factor (1)
4. Filgrastim (r-metHuG-CSF): The first 10 years
5. Hematopoieitic growth factors - Not whether, but when and where
6. American society of clinical oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
7. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
8. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia
9. Interventional antimicrobial therapy in febrile neutropenic patients
10. Antimikrobielle Therapie yon unerklärtem Fieber bei Neutropenie; Standardempfehlungen der Arbeitsgemeinschaft Infektiologie in der Hämatologie und Onkologie der Deutschen Gesellschaft für Hämatologie und Onkologie
11. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients
12. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer
13. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors
14. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial
15. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
16. A prospective evaluation of the activity of human granulocytecolony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma
17. Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia-a randomized phaseIII study
18. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with highrisk acute lymphoblastic leukemia
19. Filgrastim during combination chemotherapy of patients with poorprognosis metastatic germ cell malignancy
20. Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS
21. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia
22. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia
23. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma
24. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with antibiotics in the treatment of febrile neutropenia in children
25. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer
26. Granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia
27. Update of recommendations for the use of hematopoietic colony stimulating factors: Evidence-based clinical practice guidelines
28. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia
29. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients
30. Combined transplantation of allogeneic bone marrow and CD34+ blood cells
31. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma
32. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma
33. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation
34. The evolution of clinical peripheral blood stem cell transplantation
35. Preferential mobilization and yield of normal donor primitive CD34+ Thy-1dim and CD34+ Thy-1dim CD38-progenitor cells and lymphoid subsets for allogeneic blood stem cell transplantation: Possible predictors of clinical outcome
36. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts
37. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial
38. Granulocyte colony-stimulating factor in established febrile neutropenia: A randomized study of pediatric patients
39. Simultaneous supra- and infradiaphragmatic irradiation in Hodgkin's disease
40. The effects of conventionally fractionated, extended portal radiotherapy on the human peripheral blood count
41. Analysis of weekly complete blood counts in patients receiving standard fractionated partial body radiation therapy
42. Comparison of two strategies for the treatment of radiogenic leukopenia using granulocyte colony stimulating factor
43. Granulocyte colony-stimulating factor treatment of leucopenia during fractionated radiotherapy
44. GCSF treatment of leucopenia during fractionated radiotherapy
45. Use of recombinant granulocytecolony stimulating factor to treat neutropenia occurring during craniospinal irradiation
46. The use of G-CSF during craniospinal irradiation
47. Effect of recombinant human granulocyte colony stimulating factor (R-metHuG-CSF) as an adjunct to large-field radiotherapy: A phase I study
48. Effect of filgrastim (G-CSF) in Hodgkin's disease patients treated with radiation therapy
49. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group
50. A doubleblind controlled study of granulocyte colonystimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia
51. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490)
52. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation
53. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia
54. G-CSF (Lenograstim) after chemotherapy for acute myeloid leukemia: A placebo controlled trial
55. No increase of leukemia relapse in newly diagnosed patients with acute myeloid leukemia who received granulocyte colony-stimulating factor for lifethreatening infection during remission induction and consolidation therapy
56. A randomized doubleblind, placebo-controlled phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia
57. Recombinant murine granulocyte-macrophage colony-stimulating factor augments neutrophil recovery and enhances resistance to infections in myelosuppressed mice
58. Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia
59. Peripheral bood progenitor cell transplantation: Where do we stand?
60. Mobilisation of Ph-negative blood progenitor cells with chemotherapy and rhuG-CSF in chronic myelogenous leukaemia patients with a poor response to interferon-alpha
61. Autografting with philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia
62. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: Results from a randomized phase II study and long-term follow-up of 71 patients
63. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy
64. Trilineage recovery by long-term combination therapy with recombinant human granulocyte-stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia
65. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin
66. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes
67. Transient increase in blasts mimicking acute leukemia and progressing myelodysplasia in patients receiving growth factor
68. Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer
69. Granulocyte colonystimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone marrow transplantation
70. Hematopoietic growth factors and treatment of testicular cancer: Biological interactions, routine use and dose-intensive chemotherapy
71. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis
72. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease
73. Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: Updated results of the German Hodgkin's Lymphoma study group
74. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: A prospective randomized study of 300 patients
75. Improving survival without reducing quality of life in smallcell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: Results of a British Medical Research Council Multicenter Randomized Trial
76. Placebo controlled double blind trial of recombinant human granulocyte colony-stimulating factor for bone marrow transplantation
77. Recombinant human granulocyte colony-stimulating factor in allogeneic bone marrow transplantation
78. A phase III randomized placebo-controlled study in 315 pediatric and adult autologous or allogeneic bone marrow transplantation with lenograstim 5 g/kg/day (glycosylated rHu-G-CSF)
79. Long-term effects of the lenograstim therapies in allogeneic bone marrow transplantation
80. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation
81. Placebo-controlled phase III trial of lenograstim in bonemarrow transplantation
82. A controlled trial of recombinant human granulocyte-macrophage colony stimulating factor after total body irradiation, high dose chemotherapy and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma
83. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation
84. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells
85. Effect of peripheralblood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy
86. Allogeneic blood stem cell transplantation: Considerations for donors
87. Transplantation of allogeneic CD34+ blood cells
88. Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro
89. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38-progenitor cells
90. Transplantation of bone marrow as compared with peripheralblood cells from HLA-identical relatives in patients with hematologic cancers
91. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders. Current practice in Europe in 1996 and proposals for an operational classification
92. Transplantation of peripheral blood progenitor cells from unrelated donors
93. Recombinant human GM-CSF treatment of neutropenia in glycogen storage disease-1b
94. Improvement of newtropenia and neutrophil dysfunction by granulocyte colony-stimulating factor in a patient with glycogen storage disease type lb
95. Granulocyte transfusions: Efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation
96. Kinetic of hematopoietic reconstitution after multiple consecutive courses of intensive chemotherapy supported with granulocyte-colony stimulating factor and peripheral blood progenitor cells
97. A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis
98. Highdose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells
99. Efficacy of delayed granulocyte colony-stimulating factor after autologous BMT